No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Codexis, Inc. specializes in the invention, advancement, and commercialization of enzymes and various other proteins. Their diverse portfolio encompasses biocatalyst solutions, chemical intermediates designed for subsequent processing, and specialized Codex biocatalyst panels and kits that empower clients to conduct effective chemistry screening. Additionally, the company delivers expertise in biocatalyst screening and protein engineering services. A cornerstone of their operations is the proprietary CodeEvolver protein engineering technology platform. This platform is instrumental in crafting and deploying biocatalysts that facilitate chemical transformations, significantly boosting the efficiency and output of manufacturing processes. Beyond manufacturing applications, CodeEvolver also plays a vital role in identifying novel biotherapeutic drug candidates for specific human ailments, alongside its use in molecular biology and the development of in vitro diagnostic enzymes. Codexis markets its offerings directly to pharmaceutical manufacturers across the United States and Europe, leveraging its dedicated sales and business development teams. Established in 2002, the company maintains its headquarters in Redwood City, California.
www.codexis.comNo one on the platform currently holds 0I0X.L.
No tracked institution reports a position in 0I0X.L as of their last filing.
No one on the platform has traded 0I0X.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 18.6% | 0.4% | ||||
| Profit Margin % | -62.5% | -65.1% | -45.9% | |||
| Free Cash Flow Margin % | -33.9% | -46.1% | -33.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $74M | +10.1% | $-0.37 | $-0.43–$-0.34 | — | 1 |
| 2027 | $88M | +19.4% | $-0.27 | $-0.32–$-0.25 | — | 1 |
| 2028 | $117M | +32.8% | $-0.05 | $-0.06–$-0.05 | — | 1 |
| 2029 | $139M | +18.5% | $0.07 | $0.07–$0.08 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.14 | $-0.13 | +8.2% |
| 2026-05-07 | $-0.14 | $-0.10 | +26.8% |
| 2026-03-11 | $-0.03 | $0.11 | +466.7% |
| 2025-11-06 | $-0.15 | $-0.22 | -48.1% |
| 2025-08-13 | $-0.19 | $-0.16 | +17.6% |
| 2025-05-14 | $-0.24 | $-0.25 | -5.4% |
| 2025-02-27 | $-0.04 | $-0.13 | -252.1% |
| 2024-11-01 | $-0.24 |
| $-0.29 |
| -20.0% |
| +4.37% |
| $92M |
| — |
| 0HX7.LAdicet Bio, Inc. | $9.11 | +11.10% | $47M | — |
| 0IFK.LEditas Medicine, Inc. | $2.80 | +3.48% | $259M | — |
Source: Financial Modeling Prep · peers by sector/industry